Creyon Bio, Inc. has announced a global licensing and multi-target research collaboration with Eli Lilly and Company focused on the discovery, development and commercialization of novel RNA-targeted oligonucleotide therapies for a broad range of diseases. The collaboration aims to leverage Creyon's AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly's named targets to make therapies safer and more effective for patients with rare and common diseases.